Optimized antibodies that target CD19

US11618788B2 · kind B2 · utility

Assignee

• Xencor, Inc. · US

Inventors

• Matthew Bernett · Monrovia, US
• Seung Chu · Cypress, US
• John Desjarlais · Pasadena, US
• Sher Bahadur Karki · Pasadena, US
• Gregory Alan Lazar · Los Angeles, US
• Erik Weiking Pong · Temple City, US
• John O. Richards · Duarte, US
• Eugene Zhukovsky · West Hollywood, US

Key dates

• Filing date: Apr 1, 2020
• Grant date: Apr 4, 2023
• Expiry date: May 24, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.